Page 3 - Ross Jeggo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Servier and Oncodesign Announce the Selection of a Preclinical Candidate as Part of Their Collaboration Targeting New Treatments for Parkinson s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinsons disease
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs. They are small oligonucleotides, similar to siRNAs. This technology is MiNA’s focus, based on inventions from the company’s founder Pål Saetrom, which were assigned to MiNA by the Norwegian University of Science and Technology. The company has also in-licensed fundamental patents from UT Southwestern Medical Center that covers RNA activation therapeutics.
MiNA will leverage its saRNA platform to identify possible treatments to restore normal cell function in neurological diseases. Servier will handle preclinical and clinical development of potential candidates. Servier also will have the option for commercialization of any products coming out of the partnership.
Servier and MiNA Therapeutics ink neurology pact
22nd January 2021
French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
Under the terms of the deal, MiNA will engage its saRNA platform to identify new potential treatments with the aim of restoring normal cell function in neurological disorders.
Meanwhile, Servier will be responsible for preclincial and clinical development of the lead candidates and will retain the rights for the commercialisation of any products resulting from the partnership.
Although details of the specifics of the deal are sparse, the companies disclosed that MiNA would receive an upfront payment and exclusivity fee for certain ‘targets of interest’.
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005329/en/
As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialization of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics
vimarsana © 2020. All Rights Reserved.